Submitted by Anonymous (not verified) on 19 May 2026 - 11:10
Human medicines European public assessment report (EPAR): Arexvy, Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted), Date of authorisation: 06/06/2023, Revision: 11, Status: Authorised
Source: